Abstract: A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein a content of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole in the adhesive agent layer is 5 to 13.2% by mass relative to a total mass of the adhesive agent layer.

Abstract: The present invention relates to methods for coating at least one surface of a medical device for improving the hemocompatibility of said surface. Further, the invention relates to medical devices comprising surfaces, coated with a coating composition containing a nonionic ester formed from an acyclic C3-C6(OH)3-6 polyol and from at least three C12-C26 fatty acids, and further includes at least one hydrophilic group.

Abstract: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.

Abstract: The invention is directed to formulations comprised of multiple dietary and endogenously made antioxidants and B-vitamins and the use of these formulations in preventing and treating coronary artery disease.

Abstract: Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are pharmaceutical compositions and kits for the treatment or prevention of chronic pain or convulsion.

Abstract: Described herein is a physiologically-balanced, acidic solution. Typically the solution is prepared by a chemical reactions or by the electrolysis of a solution comprising a mixture of an inorganic salt to form a physiologically balanced solution. This invention also relates to methods for use of the solutions, including a specialized bandage which may be used in combination with the solutions, or optionally with other topically applied materials. A mixture of inorganic salts and, optionally minerals, is used in order to mimic the electrolyte concentration and mixture of body fluid in an isotonic state. The solution typically comprises of one halide salt of lithium, sodium, potassium, calcium, and other cations. Typically the halide is fluoride, chloride, bromide, or iodide, and most typically chloride.

Abstract: The present invention provides a method for suppressing hemolytic anemia by selectively ameliorating reticulocyte increase and iron deposition on spleen caused as the side effects of methionine. The present invention also provides an appetite suppressor with reduced such side effects, where threonine is used as the effective ingredient of the suppressor of hemolytic anemia due to methionine and a combination of methionine and threonine is used as the effective ingredient of the appetite suppressor.

Abstract: The present invention provides a composition for osteoinduction, which comprises a complexed-acidic-phospholipid complex containing calcium, phospholipid, and inorganic phosphate combined with collagen in a composite form. The composition is effective to promote new bone formation upon introduction of the composition into various osseous defects.

Abstract: Pentafluorosulfanylbenzoylguanidines of the formula I and II in which R1 to R4 have the meanings stated in the claims, are suitable as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.

Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.

Abstract: The invention relates to a fluid that can be used for preventing or treating hypohydration and the secondary consequences thereof. The fluid comprises one or more carbohydrates and minerals and is further characterized by a low osmolarity. The invention further relates to the use of such a fluid for medical, dietetic and other applications.

Abstract: A combination of 2-acetoxy-5-(?-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus.

Abstract: Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.

Abstract: The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism. The present invention is also directed to methods of decreasing cholesterol levels.

Abstract: Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.

Abstract: The present invention provides a method of using anti-hypertensive agents (“AHAs”) to attenuate the transient increase in blood pressure observed in patients where Vascular Targeting Agents (“VTAs”) are administered to treat diseases associated with malignant neovascularization. The invention also relates to pharmaceutical compositions comprising AHAs and VTAs, and to kits thereof.

Abstract: Method of producing a physiologically acceptable ketosis such as to treat a patient in need of therapy for one or more of Amylotrophic lateral sclerosis, Free Radical disease, Heart failure and Duchenne's muscular dystrophy by oral administration to the patient of a cyclic oligomer of formula (I) where n is an integer of 1 or more or a complex thereof with one or more cations or a salt thereof, wherein the physiologically acceptable ketosis is characterized by blood levels of (R)-3-hydroxybutyrate of from 0.5 to 20 mM.

Abstract: This invention provides for the treatment of inflammatory, cancer and thrombotic disorders through the administration, in combination, of a COX2 inhibitor, low dose aspirin, and antioxidant flavanoids, flavonoids or isoflavones and at least one of these combinations will be given in a subtherapeutic amount for improved anti-inflammatory, anti-cancer, and anti-thrombotic efficacy and safety.

Abstract: This invention generally relates to methods for treating or preventing an inflammatory disease or disorder comprising administering to a patient in need thereof an effective amount of a Pyrazoloanthrone Derivative having the following structure: or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.